Evidence map›Paper›PMID 38933181›Full record

ReviewPulmonary circulation2024

A perfectly imperfect engine: Utilizing the digital twin paradigm in pulmonary hypertension.

Melody Walker, Helen Moore, Ali Ataya, Ann Pham, Paul A Corris, Reinhard Laubenbacher, Andrew J Bryant

Abstract readReview
In one paragraph

Review in Pulmonary circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Challenges and opportunities in uncertainty quantification for healthcare and biological systems.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Melody WalkerUniversity of Florida College of Medicine Gainesville Florida USA.
Helen MooreUniversity of Florida College of Medicine Gainesville Florida USA.
Ali AtayaUniversity of Florida College of Medicine Gainesville Florida USA.ORCID 0000-0001-8505-1680
Ann PhamUniversity of Florida College of Medicine Gainesville Florida USA.
Paul A CorrisThe Faculty of Medical Sciences Newcastle University Newcastle upon Tyne UK.
Reinhard LaubenbacherUniversity of Florida College of Medicine Gainesville Florida USA.
Andrew J BryantUniversity of Florida College of Medicine Gainesville Florida USA.ORCID 0000-0001-9433-3049

Funding

Multiscale modeling of the role of heme during invasive pulmonary aspergillosisR01AI135128 · NIAID · UNIVERSITY OF FLORIDA · PI REINHARD LAUBENBACHER, Borna Mehrad · 2018 to 2026
$4.9M
Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumoniaR01HL169974 · NHLBI · UNIVERSITY OF FLORIDA · PI REINHARD LAUBENBACHER, Borna Mehrad · 2023 to 2026
$2.9M
NHLBI NIH HHS R01 HL169974NIAID NIH HHS R01 AI135128
6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a severe medical condition with a number of treatment options, the majority of which are introduced without consideration of the underlying mechanisms driving it within an individual and thus a lack of tailored approach to treatment. The one exception is a patient presenting with apparent pulmonary arterial hypertension and shown to have vaso-responsive disease, whose clinical course and prognosis is significantly improved by high dose calcium channel blockers. PH is however characterized by a relative abundance of available data from patient cohorts, ranging from molecular data characterizing gene and protein expression in different tissues to physiological data at the organ level and clinical information. Integrating available data with mechanistic information at the different scales into computational models suggests an approach to a more personalized treatment of the disease using model-based optimization of interventions for individual patients. That is, constructing digital twins of the disease, customized to a patient, promises to be a key technology for personalized medicine, with the aim of optimizing use of existing treatments and developing novel interventions, such as new drugs. This article presents a perspective on this approach in the context of a review of existing computational models for different aspects of the disease, and it lays out a roadmap for a path to realizing it.

Indexed as

computational modelingpulmonary hypertensiontreatment

Identifiers

PMID38933181
PMCPMC11199193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.